Soleno Therapeutics Shares Drop 26.59% Following Safety Concerns Over Vykat XR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy SLNO?
Source: Businesswire
- Stock Price Plunge: Following a report from Scorpion Capital labeling Soleno's sole product, Vykat XR, as overpriced and potentially unsafe for children, the company's shares fell by $5.73 on August 15, 2025, representing a decline of approximately 7.41%.
- Rising Discontinuation Rate: During the quarterly earnings call on November 4, 2025, Soleno's CEO disclosed that the discontinuation rate for Vykat XR due to adverse effects was around 8% at the end of Q3 2025, raising further concerns among investors.
- Significant Stock Drop: Following the earnings report, Soleno's stock plummeted by $16.98, or 26.59%, from $63.85 to $46.87 on November 5, 2025, reflecting strong investor apprehension regarding product safety.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Soleno and its senior management on behalf of investors, which could have significant implications for the company's future legal and financial standing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.940
Low
75.00
Averages
110.50
High
125.00
Current: 52.940
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the lead plaintiff deadline on May 5, 2026, for the securities class action against Soleno Therapeutics (NASDAQ:SLNO), concerning those who purchased shares between March 26, 2025, and November 4, 2025.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, causing a 27% drop in stock price in a single day, reflecting market disappointment in its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, to assist in the investigation of Soleno's practices.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Rights Protection: Monteverde Law Firm is investigating Citizens National Corporation (CZNL) related to its sale to Peoples Bancorp, Inc., where shareholders are expected to receive 2.10 common shares of Peoples and $8.00 in cash per share, aiming to ensure fair compensation for shareholders in the transaction.
- Merger Transaction Analysis: Helix Energy Solutions Group, Inc. (HLX) is merging with Hornbeck Offshore Services, Inc., which will allow Helix shareholders to own approximately 45% of the combined company, indicating strong competitive positioning post-merger.
- Pharmaceutical Acquisition Dynamics: Apellis Pharmaceuticals, Inc. (APLS) is set to be acquired by Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and two contingent payments of $2.00 each, reflecting confidence in meeting future sales targets.
- Biotech Transaction Progress: Soleno Therapeutics, Inc. (SLNO) is being acquired by Neurocrine Biosciences, Inc., with shareholders expected to receive $53.00 per share in cash, and a shareholder vote scheduled for May 15, 2026, showcasing the company's proactive strategy in the biotech sector.
See More
Faruqi & Faruqi Investigates Soleno Investor Losses
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, focusing on investors who purchased securities between March 26, 2025, and November 4, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to safeguard their legal rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact numbers to facilitate legal support and consultation for investors.
- Potential Impact Assessment: This investigation could affect Soleno's stock price and market confidence, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Reminder of Class Action Lawsuit for Soleno Therapeutics
- Class Action Notification: Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, or risk not being represented in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug in clinical trials, leading to increased safety risks and potential legal repercussions, which adversely affected the drug's commercial viability.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and resource advantages, prompting investors to choose their legal counsel wisely.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, with participation in the class action not dependent on being a lead plaintiff, allowing investors to remain passive or hire their own counsel.
See More
Reminder for Soleno Therapeutics Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions after the drug's commercialization.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with a proven track record to ensure effective legal representation in class actions, avoiding firms that merely act as intermediaries.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the lead plaintiff deadline on May 5, 2026, for the securities class action against Soleno Therapeutics (NASDAQ:SLNO), concerning those who purchased shares between March 26, 2025, and November 4, 2025.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, causing a 27% drop in stock price in a single day, reflecting market disappointment in its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, to assist in the investigation of Soleno's practices.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Rights Protection: Monteverde Law Firm is investigating Citizens National Corporation (CZNL) related to its sale to Peoples Bancorp, Inc., where shareholders are expected to receive 2.10 common shares of Peoples and $8.00 in cash per share, aiming to ensure fair compensation for shareholders in the transaction.
- Merger Transaction Analysis: Helix Energy Solutions Group, Inc. (HLX) is merging with Hornbeck Offshore Services, Inc., which will allow Helix shareholders to own approximately 45% of the combined company, indicating strong competitive positioning post-merger.
- Pharmaceutical Acquisition Dynamics: Apellis Pharmaceuticals, Inc. (APLS) is set to be acquired by Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and two contingent payments of $2.00 each, reflecting confidence in meeting future sales targets.
- Biotech Transaction Progress: Soleno Therapeutics, Inc. (SLNO) is being acquired by Neurocrine Biosciences, Inc., with shareholders expected to receive $53.00 per share in cash, and a shareholder vote scheduled for May 15, 2026, showcasing the company's proactive strategy in the biotech sector.
See More
Faruqi & Faruqi Investigates Soleno Investor Losses
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, focusing on investors who purchased securities between March 26, 2025, and November 4, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to safeguard their legal rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact numbers to facilitate legal support and consultation for investors.
- Potential Impact Assessment: This investigation could affect Soleno's stock price and market confidence, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Reminder of Class Action Lawsuit for Soleno Therapeutics
- Class Action Notification: Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, or risk not being represented in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug in clinical trials, leading to increased safety risks and potential legal repercussions, which adversely affected the drug's commercial viability.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and resource advantages, prompting investors to choose their legal counsel wisely.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, with participation in the class action not dependent on being a lead plaintiff, allowing investors to remain passive or hire their own counsel.
See More
Reminder for Soleno Therapeutics Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions after the drug's commercialization.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with a proven track record to ensure effective legal representation in class actions, avoiding firms that merely act as intermediaries.
See More
